Dr. Eyal Talor
Articles by Dr. Eyal Talor
| 6 min read
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies
Page 1 of 1 - 1 Total Items
This person does not yet have a bio.
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discover how supercritical fluids expand chromatographic capabilities across diverse analytical challenges.
Evolving approaches to conjugation chemistry and linker–payload design are helping address persistent challenges in bioconjugate development.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.
